Skip to main content

Mycapssa FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (First approved June 26, 2020)
Brand name: Mycapssa
Generic name: octreotide
Dosage form: Delayed-Release Capsules
Company: Chiasma, Inc.
Treatment for: Acromegaly

Mycapssa (octreotide) is an oral formulation of the approved somatostatin analog octreotide for the treatment of acromegaly.

Development timeline for Mycapssa

DateArticle
Jun 26, 2020Approval FDA Approves Mycapssa (octreotide) Oral Somatostatin Analog for Acromegaly
Jan 13, 2020Chiasma Announces FDA Acceptance of Mycapssa New Drug Application Resubmission
Apr 15, 2016FDA Issues Complete Response Letter for Mycapssa New Drug Application
Aug 17, 2015Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
Jun 15, 2015Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly

See also

Mycapssa (octreotide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer